Over the past 25 years, the use of 5-MeO-DMT in informal and underground settings has contributed a substantial, yet underrecognized, body of knowledge relating to the efficacy of 5-MeO-DMT in alleviating depressive symptoms. Traditional models of drug development, typically characterized by structured trials and regulatory milestones, rarely consider findings from these alternative routes. The...
Recent research has shown potential for psychedelic therapeutics as addiction treatments; however, some academic institutions, commercial entities, and individuals are attempting to monopolize psychedelic compounds through exploiting the patent process. This Perspective article describes efforts that have been devised to mitigate exclusionary patent practices pertinent to psychedelic...
Abstract The resurgence of mainstream psychedelic research has spurred a capitalist interest in patenting to exclude competitors from producing, using, or selling psychedelic technology. Some exploit the patenting process to monopolize well-established psychedelic knowledge with overly broad claims. If patent examiners find evidence, known as “prior art,” showing that what is claimed is known,...